Krystal Biotech
NEWS
Krystal Biotech and Foghorn Therapeutics are beginning 2020 with significant expansion projects.
Pharma and life sciences companies strengthen their leadership and boards with this week’s appointments.
Krystal Biotech Inc. announced that Krish S. Krishnan, chairman and chief executive officer, will present at the Piper Jaffray 31st Annual Healthcare Conference in New York City being held Dec. 3-5 in New York.
Even clinical trial announcements don’t slow down for Halloween. It was a typically busy week. Here’s a look.
Last week was a busy week for clinical trial results. Here’s a look at some of the top stories and reporting.
Exiting the last week of June and heading into July, a number of companies announced results from ongoing clinical trials. Here’s a look.
Krystal Biotech, Inc. announced positive results from its Phase 2 placebo-controlled clinical trial of KB103 (GEM-2) study and an update on results from Phase 1 (GEM-1) study.
KB105 is a new gene therapy candidate engineered with a Transglutaminase-1 (TGM1) gene construct to treat TGM1 deficient autosomal recessive congenital ichthyosis
Perhaps the biggest mover and shaker announcement this week was the unexpected resignation of Scott Gottlieb, commissioner of the U.S. Food and Drug Administration. Gottlieb will leave his post later this month to spend more time with his family.
JOBS
IN THE PRESS